Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:...

2025-05-20 06:00 3015

Illuccix China Phase 3 Study Completes Enrolment

MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2025-05-13 07:22 2487

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...

2025-05-08 05:00 2794

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent ...

2025-04-29 06:30 2648

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2025-04-16 06:45 2748

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-04-07 07:09 4433

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ...

2025-04-02 03:30 3152

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2025-03-21 08:38 2862

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals...

2025-03-18 06:52 3005

Telix Adds Lead-212 Isotope Production Capability

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2025-03-13 06:48 3879

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Li...

2025-03-04 05:58 2457

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq...

2025-02-26 08:49 2410

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Li...

2025-02-20 20:23 4002

Latest News

Telix at ANZSNM Annual Scientific Meeting 2025

Illuccix China Phase 3 Study Completes Enrolment

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Telix Appoints Paul Schaffer as Chief Technology Officer

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Adds Lead-212 Isotope Production Capability

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Illuccix® Approved in the United Kingdom

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix Completes Acquisition of RLS (USA) Inc.

Illuccix® Receives European Approval

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Scintimun® Commercialization Partnership with Curium Pharma